BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:05:06 2024-04-24 am EDT			5-day change	1st Jan Change
88.69 ^USD	+0.23%		+2.25%	-16.30%

Apr. 23	BIONTECH : Gets a Neutral rating from Deutsche Bank	ZD
Apr. 15	Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...

BIONTECH : Receives a Buy rating from Bryan Garnier

September 24, 2021 at 05:40 am EDT

Olga Smolentseva from Bryan Garnier retains his positive opinion on the stock with a Buy rating. The target price is still set at USD 451.

Latest news about BioNTech SE

BIONTECH : Gets a Neutral rating from Deutsche Bank	Apr. 23	ZD
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Market outlook is uncertain, but optimism prevails	Apr. 15
BioNTech SE Announces Three-Year Follow-Up Data from Phase 1 Trial with the mRNA-Based Individualized Neoantigen-Specific Immunotherapy Candidate Autogene Cevumeran	Apr. 08	CI
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	Mar. 27	MT
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	Mar. 26	DJ
European Midday Briefing : Investors Hold Back Ahead of Key Inflation Print	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 26	DJ
BioNTech gets US agency notice over default on COVID vaccine royalties	Mar. 25	RE
Moderna, Inc. prepares for the post-Covid era	Mar. 25
BioNTech gets notice from US agency over default on COVID vaccine royalties	Mar. 25	RE
BioNTech gets notice from NIH on default on royalties	Mar. 25	RE
BioNTech SE Receives Notice of Default from the NIH	Mar. 25	CI
BIONTECH : Deutsche Bank remains Neutral	Mar. 22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	Mar. 21	MT
BIONTECH : A miss is a miss	Mar. 21
BIONTECH : Deutsche Bank reaffirms its Neutral rating	Mar. 21	ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating	Mar. 21	ZD
Wall St ends higher as Fed sees three rate cuts	Mar. 20	RE
BIONTECH : Jefferies sticks Neutral	Mar. 20	ZD
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	Mar. 20	MT

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

82.7 EUR

Average target price

106.5 EUR

Spread / Average Target

+28.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-16.30%	21.33B
VERTEX PHARMACEUTICALS INCORPORATED	-0.45%	105B
REGENERON PHARMACEUTICALS, INC.	+3.61%	97.5B
ARGENX SE	+2.53%	22.19B
GENMAB A/S	-7.54%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-19.98%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+8.62%	14.09B
SAREPTA THERAPEUTICS, INC.	+22.13%	10.99B
LEGEND BIOTECH CORPORATION	-21.14%	8.63B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : Receives a Buy rating from Bryan Garnier

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs